Cubist Pharmaceuticals Inc.'s (CBST) first-quarter earnings rose 45% as strong sales of the biopharmaceutical company's infection-fighting drug Cubicin boosted revenue.
Shares were up 2% at $41.50 in recent after-hours trading as the results beat expectations. Through the close, the stock has risen nearly 29% in the past ...
No comments:
Post a Comment